多药耐药铜绿假单胞菌肺炎治疗后亚胺培南-雷巴他定耐药的演变。
Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.
机构信息
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
出版信息
Clin Infect Dis. 2022 Sep 10;75(4):710-714. doi: 10.1093/cid/ciac097.
Abstract
We report the emergence of imipenem-relebactam nonsusceptible Pseudomonas aeruginosa in 5 patients treated for nosocomial pneumonia for 10-28 days. Genome sequence analysis identified treatment-emergent mutations in MexAB-OprM and/or MexEF-OprN efflux operons that arose independently in each patient across distinct P. aeruginosa sequence types. Testing with efflux-inhibitor PAβN restored imipenem-relebactam susceptibility.
摘要
我们报告了 5 例住院肺炎患者在接受治疗 10-28 天后出现对亚胺培南-雷巴他定不敏感的铜绿假单胞菌。基因组序列分析鉴定出 MexAB-OprM 和/或 MexEF-OprN 外排操纵子在每个患者中独立出现的治疗后突变，这些患者跨越不同的铜绿假单胞菌序列类型。用外排抑制剂 PAβN 进行测试恢复了亚胺培南-雷巴他定的敏感性。
相似文献
1
Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.多药耐药铜绿假单胞菌肺炎治疗后亚胺培南-雷巴他定耐药的演变。
Clin Infect Dis. 2022 Sep 10;75(4):710-714. doi: 10.1093/cid/ciac097.
2
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.头孢他啶/阿维巴坦治疗多重耐药铜绿假单胞菌感染后，对头孢菌素/β-内酰胺酶抑制剂组合和亚胺培南/雷巴他定的耐药性同时发生并出现分歧。
J Antimicrob Chemother. 2023 May 3;78(5):1195-1200. doi: 10.1093/jac/dkad062.
3
Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during exposure to ceftazidime/avibactam in .在暴露于头孢他啶/阿维巴坦期间导致对头孢洛扎/他唑巴坦和亚胺培南/西司他丁/瑞来巴坦耐药的突变。
Microbiol Spectr. 2025 Mar 4;13(3):e0231224. doi: 10.1128/spectrum.02312-24. Epub 2025 Feb 11.
4
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.耐碳青霉烯类铜绿假单胞菌 XDR 高危克隆中头孢洛扎他唑巴坦和亚胺培南/雷巴他定体外耐药发展的动力学和机制比较分析。
J Antimicrob Chemother. 2022 Mar 31;77(4):957-968. doi: 10.1093/jac/dkab496.
5
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.头孢地尔肟、亚胺培南/雷巴他定、头孢吡肟/他唑巴坦和头孢吡肟/齐多夫定对头孢他啶/他唑巴坦和头孢噻肟/阿维巴坦耐药铜绿假单胞菌的活性。
J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241.
6
In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022.2022年台湾地区头孢吡肟-他唑巴坦、头孢托罗-他唑巴坦、头孢他啶-阿维巴坦、亚胺培南-瑞来巴坦及其他对照药物对亚胺培南不敏感铜绿假单胞菌的体外活性
Int J Antimicrob Agents. 2025 Sep;66(3):107550. doi: 10.1016/j.ijantimicag.2025.107550. Epub 2025 Jun 4.
7
Activity of imipenem-relebactam, ceftolozane-tazobactam and comparators against clinical isolates of Enterobacterales and Pseudomonas aeruginosa causing severe infections in hematological and oncological patients: A prospective multicenter study.亚胺培南-瑞来巴坦、头孢托罗-他唑巴坦及对照药物对血液科和肿瘤科患者中引起严重感染的肠杆菌科细菌及铜绿假单胞菌临床分离株的活性：一项前瞻性多中心研究。
Int J Antimicrob Agents. 2025 Sep;66(3):107534. doi: 10.1016/j.ijantimicag.2025.107534. Epub 2025 May 8.
8
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、亚胺培南/雷巴坦、美罗培南/沃巴坦和对照药物对皮肤软组织感染患者分离的铜绿假单胞菌的抗菌活性。
Int J Infect Dis. 2021 Dec;113:279-281. doi: 10.1016/j.ijid.2021.10.022. Epub 2021 Oct 17.
9
Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.美罗培南-雷巴他定对 2015-2017 年美国多重耐药铜绿假单胞菌的活性-SMART。
Diagn Microbiol Infect Dis. 2019 Oct;95(2):212-215. doi: 10.1016/j.diagmicrobio.2019.05.001. Epub 2019 May 8.
10
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).新型β-内酰胺/β-内酰胺酶抑制剂组合对来自美国医疗中心的铜绿假单胞菌分离株的比较活性（2020 - 2021年）
Int J Antimicrob Agents. 2023 Apr;61(4):106744. doi: 10.1016/j.ijantimicag.2023.106744. Epub 2023 Feb 3.
引用本文的文献
1
Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.突破耐药性：新型β-内酰胺酶抑制剂（阿维巴坦、瓦博巴坦、瑞来巴坦）抗多重耐药超级细菌的比较综述
Antibiotics (Basel). 2025 May 21;14(5):528. doi: 10.3390/antibiotics14050528.
2
Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in .突变预防浓度以及对经典和新型β-内酰胺类药物第一步耐药机制的表型和基因组分析
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0194224. doi: 10.1128/aac.01942-24. Epub 2025 Mar 11.
3
Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during exposure to ceftazidime/avibactam in .在暴露于头孢他啶/阿维巴坦期间导致对头孢洛扎/他唑巴坦和亚胺培南/西司他丁/瑞来巴坦耐药的突变。
Microbiol Spectr. 2025 Mar 4;13(3):e0231224. doi: 10.1128/spectrum.02312-24. Epub 2025 Feb 11.
4
Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study).亚胺培南-瑞来巴坦治疗难治性铜绿假单胞菌感染作为挽救疗法的真实世界经验（IMRECOR研究）
Infect Dis Ther. 2025 Jan;14(1):283-292. doi: 10.1007/s40121-024-01077-z. Epub 2024 Nov 29.
5
Evolutionary loss of an antibiotic efflux pump increases quorum sensing mediated virulence .抗生素外排泵的进化性缺失增强了群体感应介导的毒力。
Res Sq. 2024 Nov 12:rs.3.rs-5391023. doi: 10.21203/rs.3.rs-5391023/v1.
6
In vivo divergent evolution of cross-resistance to new β-lactam/β-lactamase inhibitor combinations in Pseudomonas aeruginosa following ceftazidime/avibactam treatment.在接受头孢他啶/阿维巴坦治疗后，铜绿假单胞菌对新型β-内酰胺/β-内酰胺酶抑制剂组合产生交叉耐药性的体内趋异进化。
Infection. 2025 Apr;53(2):635-647. doi: 10.1007/s15010-024-02432-5. Epub 2024 Nov 8.
7
Monitoring of Pseudomonas aeruginosa mutational resistome dynamics using an enrichment panel for direct sequencing of clinical samples.使用临床样本直接测序的富集面板监测铜绿假单胞菌突变耐药组动力学。
EBioMedicine. 2024 Oct;108:105367. doi: 10.1016/j.ebiom.2024.105367. Epub 2024 Sep 26.
8
Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria.多药耐药革兰氏阴性菌中外排泵介导的对新型β-内酰胺类抗生素的耐药性
Commun Med (Lond). 2024 Aug 29;4(1):170. doi: 10.1038/s43856-024-00591-y.
9
Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms.并非所有耐碳青霉烯铜绿假单胞菌菌株都相同：根据耐药机制调整抗生素治疗。
Curr Opin Infect Dis. 2024 Dec 1;37(6):594-601. doi: 10.1097/QCO.0000000000001044. Epub 2024 Sep 18.
10
Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing complex and difficult-to-treat resistance (DTR) infections: a single-center preliminary experience.亚胺培南/西司他丁/瑞来巴坦在治疗产KPC的复杂且难治性耐药（DTR）感染中的真实世界应用：单中心初步经验
Front Microbiol. 2024 Jul 16;15:1432296. doi: 10.3389/fmicb.2024.1432296. eCollection 2024.
本文引用的文献
1
Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.通过修饰铜绿假单胞菌 MexCD-OprJ 外排泵，新型头孢菌素-β-内酰胺酶抑制剂组合出现耐药性。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0008921. doi: 10.1128/AAC.00089-21.
2
The Building Blocks of Antimicrobial Resistance in : Implications for Current Resistance-Breaking Therapies.抗菌药物耐药性的构成要素：对当前抗耐药性治疗的启示
Front Cell Infect Microbiol. 2021 Apr 16;11:665759. doi: 10.3389/fcimb.2021.665759. eCollection 2021.
3
Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.治疗中出现对头孢洛扎他唑巴坦耐药后，多重耐药铜绿假单胞菌的易感性。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00084-21.
4
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.铜绿假单胞菌流行高危克隆及其与水平获得性β-内酰胺酶的关系：2020 年更新。
Int J Antimicrob Agents. 2020 Dec;56(6):106196. doi: 10.1016/j.ijantimicag.2020.106196. Epub 2020 Oct 9.
5
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.可改变的头孢洛扎他唑巴坦耐药出现的危险因素。
Clin Infect Dis. 2021 Dec 6;73(11):e4599-e4606. doi: 10.1093/cid/ciaa1306.
6
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).一项比较亚胺培南/西司他丁/雷巴他定与哌拉西林/他唑巴坦治疗成人医院获得性或呼吸机相关性细菌性肺炎疗效和安全性的随机、双盲、多中心试验（RESTORE-IMI 2 研究）。
Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803.
7
In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa.铜绿假单胞菌对亚胺培南和亚胺培南/雷巴他定耐药性的体外动力学和机制。
J Antimicrob Chemother. 2020 Sep 1;75(9):2508-2515. doi: 10.1093/jac/dkaa206.
8
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.亚胺培南-雷巴坦对大量铜绿假单胞菌临床分离株和同源β-内酰胺耐药突变株的活性。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.02165-19.
9
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.RESTORE-IMI 1 研究：一项比较亚胺培南/雷巴他定与多黏菌素 E 联合亚胺培南治疗对亚胺培南耐药的细菌感染患者的疗效和安全性的多中心、随机、双盲试验。
Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. doi: 10.1093/cid/ciz530.
10
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.评价亚胺培南与雷巴他定联合应用对铜绿假单胞菌活性的体外研究。
BMC Microbiol. 2019 Jul 4;19(1):150. doi: 10.1186/s12866-019-1522-7.
Zotero 插件